

Leroy A. Richardson,
*Chief, Information Collection Review Office,
 Office of Scientific Integrity, Office of the
 Associate Director for Science, Office of the
 Director, Centers for Disease Control and
 Prevention.*

[FR Doc. 2014-21379 Filed 9-8-14; 8:45 am]

BILLING CODE 4163-18-P

**DEPARTMENT OF HEALTH AND
 HUMAN SERVICES**

**Centers for Disease Control and
 Prevention**

**Georgia Tuberculosis Outbreak Among
 Homeless**

AGENCY: Centers for Disease Control and
 Prevention (CDC), Department of Health
 and Human Services (HHS).

ACTION: Notice of award.

SUMMARY: The Centers for Disease
 Control and Prevention (CDC) located
 within the United States Department of
 Health and Human Services (HHS)
 announces a notice of award to the
 Georgia Department of Public Health,
 Tuberculosis (TB) Program. This award
 will be in the amount of \$419,095.00.

The purpose of this award is to halt
 the further spread of a drug-resistant
 strain of tuberculosis associated with
 multiple homeless shelters in Fulton
 County, Georgia.

DATES: It is expected the notice of award
 will begin on or about September 3,
 2014. The project period will be for one
 year.

FOR FURTHER INFORMATION CONTACT: Gail
 Burns-Grant, Division of Tuberculosis
 Elimination, Field Services and
 Evaluation Branch, Centers for Disease
 Control and Prevention, 1600 Clifton
 Road NE., MS E-10, Atlanta, GA 30333;
 phone: 404-639-5344; email: *GAB2@
 cdc.gov*.

SUPPLEMENTARY INFORMATION: Currently,
 the state of Georgia is experiencing a
 public health emergency in Fulton
 County where there has been extensive
 transmission of a drug-resistant strain of
 tuberculosis (TB) associated with
 multiple homeless shelters in the
 county. The Georgia Department of
 Public Health asked CDC to provide
 emergency funding for the immediate
 implementation of CDC
 recommendations provided as a result
 of a May 2014 outbreak investigation to
 prevent further transmission of this
 drug-resistant strain of tuberculosis and
 to prevent further deaths associated
 with this outbreak. Project number is
 CDC-RFA-PS14-1416.

Dated: September 4, 2014.

Ron A. Otten,
*Acting Deputy Associate Director for Science,
 Centers for Disease Control and Prevention.*

[FR Doc. 2014-21455 Filed 9-4-14; 4:15 pm]

BILLING CODE 4163-18-P

**DEPARTMENT OF HEALTH AND
 HUMAN SERVICES**

Food and Drug Administration

[Docket No. FDA-2014-N-0001]

**Advisory Committee Renewals;
 Correction**

AGENCY: Food and Drug Administration,
 HHS.

ACTION: Notice; correction.

SUMMARY: The Food and Drug
 Administration (FDA) is correcting a
 notice entitled “Advisory Committee
 Renewals” that appeared in the **Federal
 Register** of August 25, 2014 (79 FR
 50658). The document announced the
 renewal of certain FDA advisory
 committees by the Commissioner of
 Food and Drugs. The table in the
 document contained several errors. This
 document corrects those errors.

FOR FURTHER INFORMATION CONTACT: Lisa
 Granger, Office of Policy, Food and Drug
 Administration, 10903 New Hampshire
 Ave., Bldg. 32, rm. 3330, Silver Spring,
 MD 20993-0002, 301-796-9115.

SUPPLEMENTARY INFORMATION: In the
Federal Register of Monday, August 25,
 2014, in FR Doc. 2014-20017, on page
 50659 the table is corrected to read:

Name of committee	Date of expiration
Advisory Committee for Pharmaceutical Science and Clinical Pharmacology	January 22, 2016.
Gastrointestinal Drugs Advisory Committee	March 3, 2016.
Bone, Reproductive and Urologic Drugs Advisory Committee (formerly Reproductive Health Drugs Advisory Committee)	March 23, 2016.
Arthritis Advisory Committee	April 5, 2016.
Pharmacy Compounding Advisory Committee	April 25, 2016.
Anesthetic and Analgesic Drugs Advisory Committee	May 1, 2016.
Blood Products Advisory Committee	May 13, 2016.
Pulmonary-Allergy Drugs Advisory Committee	May 30, 2016.
Drug Safety and Risk Management Advisory Committee	May 31, 2016.
Science Advisory Board to the National Center for Toxicological Research	June 2, 2016.
Peripheral and Central Nervous System Drugs Advisory Committee	June 4, 2016.
Psychopharmacologic Drugs Advisory Committee	June 4, 2016.
Transmissible and Spongiform Encephalopathies Advisory Committee	June 9, 2016.
Science Board to the Food and Drug Administration	June 26, 2016.
Allergenic Products Advisory Committee	July 9, 2016.

Dated: September 3, 2014.

Jill Hartzler Warner,
*Associate Commissioner for Special Medical
 Programs.*

[FR Doc. 2014-21369 Filed 9-8-14; 8:45 am]

BILLING CODE 4164-01-P

**DEPARTMENT OF HEALTH AND
 HUMAN SERVICES**

Food and Drug Administration

[Docket No. FDA-2014-N-1049]

**Exploring the Expansion of
 Conditional Approval to Appropriate
 Categories of New Animal Drugs**

AGENCY: Food and Drug Administration,
 HHS.

ACTION: Notice.

SUMMARY: The Food and Drug
 Administration (FDA) is announcing
 that it is beginning the exploration
 process described in a stated
 performance goal in the Animal Drug
 User Fee Amendments of 2013 (ADUFA
 III) goals letter. Consistent with the
 performance goal, the FDA is inviting
 comments in regard to the Agency
 exploring the use of statutory changes to
 expand the use of conditional approval